Overview

Efficacy and Safety In Poorly Controlled Type 2 Diabetics

Status:
Completed
Trial end date:
2003-04-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to gain safety and efficacy information in patients with type 2 diabetes, who have not previously taken any oral antidiabetic medications, and who have an HbA1c value of greater than or equal to 10%, despite diet and exercise.
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Rosiglitazone